Rivaroxaban: Xarelto--recommendations for pharmacists

J Douxfils, S Michel, C Beauloye, M. Goethals, P Hainaut, Hein Heidbuchel, C. Hermans, B Ickx, Kristin Jochmans, Serge Motte, F Mullier, A. Peeters, C Scavée, P Sinnaeve, M Sprynger, V Thijs, C. Van Den Broeck, E Vandermeulen, P Verhamme, Jm Dogne

Research output: Contribution to journalArticlepeer-review

Abstract

Rivaroxaban is one of the new oral anticoagulants (NOACs). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.
Translated title of the contributionRivaroxaban: Xarelto--recommendations for pharmacists
Original languageFrench
Pages (from-to)28-36
Number of pages9
JournalJournal de Pharmacie de Belgique
Volume1
Publication statusPublished - Mar 2014

Keywords

  • anticoagulantia
  • xarelto
  • Rivaroxaban

Fingerprint

Dive into the research topics of 'Rivaroxaban: Xarelto--recommendations for pharmacists'. Together they form a unique fingerprint.

Cite this